The phase 3 trial was designed to evaluate the effectiveness of switching to camizestrant in combination with a CDK 4/6 inhibitor after the emergence of an ESR1 mutation, a key driver of resistance to endocrine therapy, according to a Feb. 26 news release from the company.
The results showed a statistically significant improvement in progression-free survival. While secondary end points — including overall survival and time to second disease progression — remain under evaluation, initial data showed a trend toward improved outcomes with the camizestrant combination.
